U.S. Market Community

PayPal is trying to shake off years of disappointment by rebuilding its checkout experience and pushing into new ways to pay, from smarter shopping tools to its own digital dollar. The bigger question is whether these bets can reignite customer and merchant momentum fast enough in a crowded payments market.Read more

The Auction Business Moat Is Fine. The Capital Allocation Is Not.Read more

Rezolve AI wants to turn shopping chats into completed purchases, handling everything from questions to checkout in one conversation. The upside is big if retailers adopt this approach quickly—but it hinges on execution and whether giants like Amazon or Shopify decide to build their own version.Read more

Charter is finishing a costly network upgrade, and the business could soon throw off a lot more cash that it can use to shrink debt and buy back shares. Even with slow customer growth, the author argues the market is overlooking hidden value in the company’s debt and the potential upside from a deal or partnership buzz.Read more

Many investors treat Kuros Biosciences like a risky drug developer, but the company now makes a bone-graft product that aims to help hospitals get similar patient results while spending less. The story hinges on surgery centers shifting toward lower-cost care, Kuros’s control over its key technology, and a few practical risks that could slow adoption.Read more

Kartoon Studios collects a big legal payout and suddenly sits on a pile of cash, yet the stock still trades as if that money might not stick. The real question is whether the company can stop burning cash and turn its well-known characters into steady deals before that cushion fades.Read more

Fortinet builds much of its security gear in-house and runs it all on one system, which can make it cheaper, faster, and easier for customers to manage. But its reliance on hardware sales and the fight for cloud customers could test whether this edge holds up as the market shifts.Read more

Vistra looks like a quiet backbone behind the boom in data centers, with long-term power deals tied to household-name tech companies. The catch is that regulators, shifting tech spending, and power-market surprises could quickly change how safe those deals and returns really are.Read more

Zevra shifts from a research-heavy biotech into a commercial company after winning approval for a first-of-its-kind treatment for an ultra-rare, serious disease. A cash boost and ongoing royalty income could help fund the launch and reduce the need to raise money, but execution still matters.Read more